The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.

Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

The phase 1/2 MANIFEST and phase 3 MANIFEST-2 trials are examining a complement to JAK inhibition that could improve responses and disease management up front in patients with myelofibrosis.

Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer.

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

Michael Wang, MD, discusses the significance of p53 mutations in mantle cell lymphoma.

Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.

Neoadjuvant treatment with cisplatin/pemetrexed plus atezolizumab, followed by maintenance atezolizumab, demonstrated early efficacy with acceptable safety in patients with resectable pleural mesothelioma.

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Jennifer K. Litton, MD, discusses the rationale for examining neoadjuvant talazoparib in patients with BRCA1/2-positive, early HER2-negative breast cancer, safety and efficacy results from NEOTALA, and next steps for research.

Krina K. Patel, MD, MSc, discusses future research directions with CAR T-cell therapy in patients with multiple myeloma.

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.

Acalabrutinib monotherapy continued to be highly active and safe in patients with relapsed/refractory mantle cell lymphoma with longer-term follow-up.

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.